UCSF Selects Filament Health Psilocybin Drug Candidate for Alzheimer’s Preclinical Study

The University of California, San Francisco (UCSF) has selected PEX010, a standardized, patented natural psilocybin drug candidate developed by Filament Health, for a new study investigating preclinical markers of Alzheimer’s disease. Red Light Holland confirmed the selection of the drug, which currently serves as a research material in more than 80 clinical and preclinical studies worldwide.

Researchers at UCSF will utilize the PEX010 compound to examine its potential impact on biological indicators associated with the early stages of Alzheimer’s. Filament Health manufactures the drug as a standardized botanical psilocybin, a process that ensures consistency in dosing and chemical composition for scientific trials. This selection follows the drug’s widespread adoption in the global research community, where it has already undergone extensive testing across various therapeutic applications.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 4, 2026

Author

GOAI